Report Phase 3 trial results for OTIVIDEX in Ménière’s disease
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 28 Feb 2021
- Delivered
- February 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of February”
What we found
Evidence strength A What the grades mean
The company announced the results of the third Phase 3 clinical trial for OTIVIDEX in February 2021, meeting the commitment to report results by the end of that month.
-
A Otonomy, Inc. 8-K filed 2021-05-11
“In February 2021, Otonomy announced the results of a third Phase 3 trial for OTIVIDEX in Ménière’s disease.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- OTIVIDEX Phase 3 trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Otonomy, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C493566-023678 · Corrections policy